In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

New personalized skin cancer treatment shows success in preventing return of high-risk melanoma - Patients with severe ...

We recently published 10 Big Names Leaving Wall Street Behind; 7 Are Hitting Record Highs. Moderna Inc. (NASDAQ:MRNA) was one ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1) The ...

KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) Results to be presented at American ...

(RTTNews) - Merck & Co. Inc. (MRK) said Tuesday that the European Commission has approved KEYTRUDA, Merck's anti-PD-1 therapy, as a monotherapy for the first-line treatment of adult patients with ...